ClinicalTrials.gg
Not yet recruitingNCT07853885Updated Oct 9, 2026

Intraosseous Tranexamic Acid for Reducing Blood Loss in Total Knee Arthroplasty

A Phase 4 interventional study of Tranexamic Acid and Normal Saline in Knee Osteoarthritis, sponsored by The Second Affiliated Hospital of Kunming Medical University. Not yet recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by The Second Affiliated Hospital of Kunming Medical University · Phase 4, Interventional, and Prevention

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing Tranexamic Acid in Osteoarthritis, Knee — 2 open to participants now, 2 under way, 1 of them phase 3. Tranexamic Acid · Osteoarthritis, Knee.

Planned enrollment
12th of 15
70 · median 100
Started
2026
the only one that year
Phase 4
7 of 15
1 open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
The Second Affiliated Hospital of Kunming Medical University

Among the 15 studies testing Tranexamic Acid in Osteoarthritis, Knee, this one is the 12th largest by planned enrollment, is the only one that started in 2026, is one of 7 in phase 4, and was the 15th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 15 studies testing Tranexamic Acid in Osteoarthritis, Knee are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Tranexamic Acid in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This prospective, single-center, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of local intraosseous tranexamic acid administration for reducing perioperative blood loss in patients undergoing primary unilateral total knee arthroplasty (TKA). A total of 70 patients with primary knee osteoarthritis will be randomly assigned in a 1:1 ratio to either the tranexamic acid group or the placebo control group. Before skin incision, participants in the experimental group will receive local intraosseous tranexamic acid, while participants in the control group will receive an equal volume of normal saline using the same injection procedure. The primary outcome is total perioperative blood loss. Secondary outcomes include postoperative hemoglobin reduction, transfusion requirements, pain, knee swelling, range of motion, functional recovery, length of hospital stay, and postoperative complications. Participants will be followed for up to 3 months after surgery.

Read the detailed description

Total knee arthroplasty may be associated with substantial perioperative blood loss. Tranexamic acid is commonly used to reduce bleeding during joint arthroplasty, but conventional systemic administration may result in greater systemic drug exposure. Local intraosseous administration may provide a higher drug concentration at the surgical site while limiting systemic exposure.

This study is a prospective, single-center, randomized, double-blind, placebo-controlled, parallel-group clinical trial. Seventy patients undergoing primary unilateral total knee arthroplasty for primary knee osteoarthritis will be randomly assigned in a 1:1 ratio to an experimental group or a placebo control group.

Before skin incision, participants in the experimental group will receive tranexamic acid by local intraosseous injection into the cancellous bone of the tibial plateau and the medial and lateral condyles of the distal femur. Participants in the control group will undergo the same procedure using an equal volume of normal saline. Surgical technique, perioperative analgesia, rehabilitation, and other routine perioperative management will be standardized between the two groups.

The primary outcome is total perioperative blood loss, assessed using perioperative hematologic measurements through postoperative day 3. Secondary outcomes include postoperative hemoglobin reduction, transfusion rate and volume, postoperative pain, knee swelling, range of motion, functional recovery, length of hospital stay, and safety outcomes such as symptomatic deep vein thrombosis, pulmonary embolism, wound complications, infection, and other adverse events. Functional recovery will be assessed during follow-up through 3 months after surgery.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Total Knee Arthroplasty
  • Tranexamic Acid
  • Intraosseous Injection
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 to 85 years.
  • Diagnosis of primary knee osteoarthritis.
  • Scheduled to undergo primary unilateral total knee arthroplasty.
  • (ASA) physical status classification I to III.
  • Willing to participate in the study and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to tranexamic acid.
  • History of thromboembolic disease, including deep vein thrombosis or pulmonary embolism.
  • Known hypercoagulable state or current use of anticoagulant therapy, except for protocol-permitted perioperative anticoagulation
  • Severe cardiac, hepatic, or renal dysfunction.
  • History of vascular stent implantation or peripheral vascular disease.
  • Active infection or previous surgery on the study knee.
  • Abnormal coagulation function, including an (INR) greater than 1.5.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Intraosseous Tranexamic Acid

    Participants assigned to this arm will receive a total dose of 2 g of tranexamic acid by local intraosseous injection before skin incision during primary unilateral total knee arthroplasty. Tranexamic acid 1 g will be administered into the cancellous bone of the tibial plateau, and the remaining 1 g will be administered into the medial and lateral condyles of the distal femur. All other surgical, analgesic, and rehabilitation procedures will follow the standardized perioperative protocol.

    Drug: Tranexamic Acid

  • Placebo comparator
    Normal Saline Placebo

    Participants assigned to this arm will undergo the same intraosseous injection procedure before skin incision during primary unilateral total knee arthroplasty but will receive an equal volume of normal saline instead of tranexamic acid. All other surgical, analgesic, and rehabilitation procedures will be identical to those in the experimental arm.

    Drug: Normal Saline

Interventions

  • A total dose of 2 g of tranexamic acid will be administered by local intraosseous injection before skin incision during primary unilateral total knee arthroplasty. Of the total dose, 1 g will be injected into the cancellous bone of the tibial plateau, and 1 g will be injected into the medial and lateral condyles of the distal femur. The intervention will be administered using a standardized intraosseous injection technique.

  • DrugNormal Saline

    Normal saline will be administered by the same local intraosseous injection procedure before skin incision during primary unilateral total knee arthroplasty. The volume, injection sites, timing, and administration procedure will be matched to those used in the experimental group.

06

What researchers measure

Primary outcomes

  1. Total Perioperative Blood Loss

    Total perioperative blood loss will be calculated in milliliters (mL) using perioperative hematologic measurements and estimated blood volume based on preoperative and postoperative laboratory values.

    Time frame: From preoperative baseline through postoperative day 3

Secondary outcomes

  1. Maximum Decrease in Hemoglobin

    Maximum decrease in hemoglobin from the preoperative value to the lowest postoperative value, expressed in g/L.

    Time frame: From preoperative baseline through postoperative day 3

  2. Allogeneic Red Blood Cell Transfusion Rate

    Proportion of participants who receive at least one allogeneic red blood cell transfusion from the start of surgery through hospital discharge.

    Time frame: From the start of surgery through hospital discharge,an anticipated average of 5-7 days.

  3. Volume of Allogeneic Red Blood Cell Transfusion

    Total volume of allogeneic red blood cells transfused from the start of surgery through hospital discharge.

    Time frame: From the start of surgery through hospital discharge,an anticipated average of 5-7 days.

  4. Pain Intensity at Rest

    Postoperative pain at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: Postoperative day 1, postoperative day 3

  5. Pain Intensity During Activity

    Postoperative pain during activity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: Postoperative day 1, postoperative day 3

  6. Knee Swelling

    Knee circumference measured 10 cm above the superior border of the patella.

    Time frame: Preoperative baseline, postoperative day 1, and postoperative day 3

  7. Knee Range of Motion

    Knee range of motion measured in degrees.

    Time frame: Preoperative baseline, postoperative day 1, and postoperative day 3

  8. Knee Functional Score

    Knee function will be assessed using the Hospital for Special Surgery (HSS) Knee Score. The total score ranges from 0 to 100, with higher scores indicating better knee function.

    Time frame: Within 24 hours before hospital discharge, 4 weeks after surgery, and 3 months after surgery

  9. Length of Hospital Stay

    Duration of postoperative hospitalization, expressed in days.

    Time frame: From the day of surgery through hospital discharge, an anticipated average of 5-7 days.

  10. Symptomatic Deep Vein Thrombosis

    Incidence of symptomatic deep vein thrombosis confirmed by vascular ultrasonography.

    Time frame: Up to 30 days after surgery

  11. Symptomatic Pulmonary Embolism

    Incidence of symptomatic pulmonary embolism confirmed by computed tomography pulmonary angiography when clinically indicated.

    Time frame: Up to 30 days after surgery

  12. Other Postoperative Complications

    Incidence of postoperative complications, including wound infection, wound drainage or poor healing, neurovascular injury, systemic allergic reaction, and abnormal liver or kidney function.

    Time frame: Up to 30 days after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 6 months is below that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPain Intensity at Rest: how it is measured was reworded
Oct 9, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 9, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPain Intensity at Rest: how it is measured was reworded
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853885
Lead sponsor
The Second Affiliated Hospital of Kunming Medical University
Responsible party
Ning Lu (Associate Professor, The Second Affiliated Hospital of Kunming Medical University) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

NIng Lu
Contact
luningwei2@163.com
+86-13888574273
Ning Lu
principal investigator · The Second Affiliated Hospital of Kunming Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion